Brighton Jones LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,005 shares of the biopharmaceutical company’s stock, valued at approximately $204,000.

Other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp raised its stake in Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after buying an additional 2,727,063 shares during the last quarter. Parnassus Investments CA raised its stake in Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. APG Asset Management N.V. raised its stake in Gilead Sciences by 16.7% in the first quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock worth $402,319,000 after buying an additional 849,741 shares during the last quarter. AQR Capital Management LLC raised its stake in Gilead Sciences by 25.7% in the first quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock worth $354,070,000 after buying an additional 1,066,172 shares during the last quarter. Finally, Swiss National Bank raised its stake in Gilead Sciences by 26.9% in the first quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock worth $317,059,000 after buying an additional 989,400 shares during the last quarter. 74.02% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.5182% during mid-day trading on Monday, hitting $72.7752. 1,414,135 shares of the company’s stock were exchanged. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.10. The firm has a 50 day moving average of $72.36 and a 200 day moving average of $68.77. The stock has a market capitalization of $95.04 billion, a P/E ratio of 7.9043 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.08 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.watchlistnews.com/brighton-jones-llc-buys-shares-of-3005-gilead-sciences-inc-nasdaqgild/1487179.html.

A number of equities research analysts recently weighed in on GILD shares. William Blair reaffirmed an “outperform” rating on shares of Gilead Sciences in a report on Friday, June 16th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Credit Suisse Group reaffirmed an “outperform” rating and set a $79.00 price target on shares of Gilead Sciences in a report on Friday, May 5th. Leerink Swann reaffirmed a “hold” rating and set a $74.00 price target on shares of Gilead Sciences in a report on Tuesday, July 25th. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 price target for the company in a report on Friday, July 28th. Twelve investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $80.31.

In related news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 206,666 shares of company stock worth $15,223,184. 1.30% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.